

Correction: mTOR inhibition affects Yap1- β -catenin-induced hepatoblastoma growth and development

Laura Molina^{1,2,*}, Hong Yang^{3,*}, Adeola O. Adebayo Michael⁴, Michael Oertel^{1,5}, Aaron Bell¹, Sucha Singh¹, Xin Chen⁶, Junyan Tao¹ and Satdarshan P. Monga^{1,5,7}

¹ Division of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

² Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

³ Department of Medical Ultrasonics, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China

⁴ Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA

⁵ Pittsburgh Liver Research Center, University of Pittsburgh Medical Center and University of Pittsburgh School of Medicine, Pittsburgh PA, USA

⁶ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, USA

⁷ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

* These authors have contributed equally to this work

Published: September 24, 2019

Copyright: Molina et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The correct author information is given below:

Satdarshan P. Monga

Original article: Oncotarget. 2019; 10:1475–1490. <https://doi.org/10.18632/oncotarget.26668>